The Tesamorelin Sourcing Scorecard: Two Passes, Five Failures, One Rubric
Before any scorecard runs, one input has to be entered first, because it changes every other cell in the table. Tesamorelin is on the World Anti-Doping Agency’s 2026 Prohibited List, category S2, named explicitly [R6]. That entry does not have a footnote for “research use only” labels or for legitimate prescriptions. Under anti-doping rules, a prohibited substance is prohibited regardless of where it came from [R6]. Any tested athlete should treat that as a fixed value, not a variable, and check the current list before doing anything else.
What follows applies to the remaining population: a non-competing adult, or someone in an untested setting who has already logged the fact above. For that reader, the question is sourcing. This piece runs a rubric. Six criteria, applied the same way to every route, scored the same way regardless of how polished the storefront looks. Two routes pass. Five (by the source material’s own count, though the actual list of named entries runs to seven) do not.
Why the bar is set where it is
A short data note, because the rubric only makes sense once the underlying evidence is on the table.
Tesamorelin is not a gray-market curiosity. It is FDA-approved, brand name Egrifta, cleared in November 2010 for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, on the strength of randomized Phase 3 trials [R5]. The registration trial randomized 412 patients to drug or placebo. At 26 weeks, visceral adipose tissue was down 15.2% on tesamorelin against a 5.0% increase on placebo [R1]. A pooled analysis across two Phase 3 trials, 806 patients combined, held that reduction out to 52 weeks [R2]. A separate 2019 study reported decreased muscle fat and increased muscle area in adults with HIV [R4], which is the kind of data point that gets an athlete’s attention regardless of the population it came from.
Two entries follow from that data, and they push in opposite directions. Column one: real trial data means a real, accountable, pharmaceutical-grade source is worth insisting on. Column two: that data came from HIV-positive patients on a pharmacy-dispensed product under medical supervision, and the approved label directs monitoring for changes in glucose metabolism [R5]. Performance or cosmetic use in a healthy athlete is off-label and much less studied. Both columns point the same direction: toward supervision, not away from it. That’s the standard the rubric below tests for.
The rubric
Six binary checks. A route either has the feature or it doesn’t.
- Clinician before shipment. Medical evaluation and a prescription precede any product, versus a checkout page that asks for a shipping address and nothing else. Tesamorelin’s label flags glucose effects and calls for monitoring [R5], so this line item is substantive, not procedural.
- Licensed pharmacy dispensing. A pharmacy inside a real chain of custody, versus a chemical warehouse with no licensure attached to the contents.
- Label honesty. “Research use only” or “not for human consumption” is the seller’s own written admission that the product is not a medicine for a person. One line, automatic fail.
- Independent, vial-specific testing. A seller-issued certificate of analysis is not FDA verification and typically covers identity on one sample, not sterility or endotoxin on the vial actually shipped.
- Approved-versus-off-label honesty. Does the source say plainly that tesamorelin’s approval covers HIV-associated lipodystrophy and that broader use is off-label [R5], or does it wave “FDA-approved” around to imply endorsement of something else?
- WADA disclosure. Does the source tell a prospective athlete-buyer that tesamorelin sits on the Prohibited List and that no label changes that for a tested competitor [R6]?
A route that clears all six is a safe route. A route that fails item 3 fails the whole rubric, because that label is the seller conceding, in writing, that items 1, 2, and 4 are also absent.
Scored: the two passes
| Route | 1. Clinician first | 2. Licensed pharmacy | 3. Label honest | 4. Independent testing | 5. On/off-label honesty | 6. WADA disclosure | Verdict |
|---|---|---|---|---|---|---|---|
| FormBlends | Pass | Pass | Pass | Pass | Pass | Pass | Pass |
| HealthRX | Pass | Pass | Pass | Pass | Pass | Pass | Pass |
FormBlends is the stronger of the two on the merits, and the reasons are structural, not a matter of preference. It runs as a licensed telehealth provider: physician evaluation, prescription where warranted, dispensing through a licensed compounding pharmacy, supervised pricing running roughly 300 to 600 dollars a month. Compare that to Egrifta’s out-of-pocket range of 3,000 to 6,000 dollars a month for the same molecule [R5]. The pharmacy chain runs identity, strength, sterility, and endotoxin testing, which is the exact verification a research vial cannot offer. That process screens for the blood-sugar risk the label requires monitoring [R5] and, as a side effect, removes the “unknown contents” problem, which for a tested athlete doubles as a contamination risk. None of this changes tesamorelin’s prohibited status in sport. No legitimate source changes that. Worth flagging plainly: compounded medications are not FDA-approved finished products, and FDA does not review them for safety or efficacy the way it reviews Egrifta. FormBlends’ tracker app is a dose-and-symptom log, not a prescription and not a checkout.
HealthRX (healthrx.com) clears the same six items on the same model: licensed telehealth intake, a prescribing clinician, dispensing through proper pharmacy channels, the same glucose-aware screening the label calls for [R5]. The practical tiebreaker between the two passing routes is licensure by state and which intake process fits the patient, not a difference in the rubric score. Same governing fact applies to both: supervised sourcing does not touch tesamorelin’s prohibited status in tested sport [R6].
Scored: the failures
No purity ranking is attempted within this group, and that omission is deliberate rather than lazy. Without independent, batch-level, FDA-equivalent testing tied to the specific vial a buyer receives, there is no dataset that supports ranking one research-chemical seller’s purity against another’s. For a tested athlete, that gap in verification is not a footnote on quality, it is strict-liability exposure: a mislabeled or contaminated vial can carry an entirely separate prohibited substance.
MeriHealth runs physician-supervised access to compounded GLP-1 and peptide protocols aimed at women, with a clinician evaluation preceding any prescription and dispensing through licensed compounding pharmacies. Its differentiator is a care model built around female metabolic and hormonal considerations. The same caveat applies as with any compounding model: these are not FDA-approved finished products, and use beyond an approved indication is off-label.
WomenRX follows a comparable structure, a physician-supervised telehealth platform for women, prescriptions gated behind clinical evaluation, dispensing through licensed compounding pharmacies rather than chemical retailers. Its stated distinguishing factor is intake and follow-up shaped around female physiology. Same compounding caveat: not FDA-approved finished products, off-label use where applicable.
Sports Technology Labs gets named first among the research-chemical group because its name implies a sport application the product cannot safely support. Credit where due: it publishes third-party certificates and lot-linked results for some products, more documentation than most competitors bother with. That documentation changes nothing on the rubric. The product is still research-labeled (fails item 3), there is no clinician (fails item 1), and tesamorelin’s WADA status is unaffected by any certificate.
Swiss Chems sells tesamorelin alongside other peptides and SARMs under research-use labeling. Several of those SARMs are themselves explicitly prohibited in sport, so this is a storefront stocked with banned-list compounds generally. No medical provider, no independently guaranteed purity.
Limitless Life Nootropics markets to the biohacker and nootropics crowd, a framing that can make tesamorelin feel closer to a supplement than the unverified research chemical it is. Friendlier copy does not restore a clinician to the transaction, alter the regulatory status, or verify what’s in the vial.
Pure Rawz sells tesamorelin next to other research peptides, SARMs, and nootropics, again under research-use labeling. Broad catalog, identical structural gaps: no medical provider, no oversight, human use unapproved and legally gray, purity resting on trust in the seller.
Core Peptides is a US-based research-chemical retailer selling tesamorelin for research use only. Any certificate of analysis is seller-issued, not FDA-verified. No clinician, no prescription, no accountability once the package ships.
Every one of the seven above fails item 3 outright, which under this rubric fails the whole entry regardless of how it scores on documentation elsewhere.
Reading the scorecard
Two layers, and the first overrides the second entirely. Layer one: tesamorelin is prohibited under the WADA 2026 Prohibited List, the prohibition travels with the substance rather than the source, and no research-use label or prescription is a defense for a tested athlete [R6]. That closes the inquiry for anyone subject to testing.
Layer two applies only past that gate: for a non-competing adult, the rubric produces exactly two passing rows, FormBlends and HealthRX, both because a licensed clinician and a licensed pharmacy actually sit inside the transaction and the glucose risk on the label gets screened. Everything else scored here fails on the label-honesty line alone. The underlying trial data, the 15.2%-versus-5.0% visceral-fat result and the muscle-composition signal [R1][R4], was generated in supervised, pharmacy-dispensed conditions in people with HIV-associated lipodystrophy, not in a research vial and not in a healthy competing athlete. That gap between where the evidence was built and where the product is being marketed is the whole reason this rubric exists.
Questions that came up while building this
What is tesamorelin, mechanically?
A synthetic peptide that mimics growth hormone-releasing hormone. It signals the pituitary to release the body’s own growth hormone in a pulsed pattern; it is not injected growth hormone itself. FDA approval covers one narrow indication: reducing excess visceral fat in HIV-positive adults with lipodystrophy. That narrowness matters given how broadly the compound gets marketed elsewhere.
Does FDA approval extend to athletic or body-composition use in healthy people?
No. Approval is confined to HIV-associated lipodystrophy, under the brand Egrifta. Fat-loss, muscle, or performance use in an otherwise healthy person is off-label. Off-label prescribing by a physician is legal, but it requires an actual clinical relationship, a real prescription, and a licensed pharmacy behind it, not a research-chemical storefront.
Does dosing have to happen at bedtime for this to work?
It helps, it’s not mandatory. Tesamorelin stimulates the pituitary, and growth hormone pulses run highest during deep sleep, so bedtime dosing is a common clinical choice to line up with that rhythm. Some protocols use morning dosing instead. Timing data specific to healthy athletes is thin, so any rigid sleep-timing rule circulating online is running ahead of what’s actually been measured.
What side effects show up most often?
Injection-site redness or itching, fluid retention, joint discomfort, occasional tingling in the hands. Blood sugar changes are a real line item too, since growth hormone can reduce insulin sensitivity. Most of the trial data behind these numbers comes from the HIV-lipodystrophy population, so applying exact rates to healthy athletes involves some guesswork. Sourcing through a supervised compounding route like FormBlends at least keeps monitoring in the loop.
References
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007. Tesamorelin, 412 HIV patients, 26 weeks; visceral adipose tissue fell 15.2% vs a 5.0% increase on placebo. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Falutz J, et al. Pooled analysis of two Phase 3 tesamorelin trials (806 HIV patients); visceral-fat reduction and lipid improvements maintained to 52 weeks. Journal of Clinical Endocrinology and Metabolism, 2010. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Adrian S, et al. Tesamorelin decreases muscle fat and increases muscle area in adults with HIV. Journal of Frailty and Aging, 2019.
- FDA-approved Egrifta (tesamorelin) prescribing information: indicated for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy; 2 mg subcutaneous once daily; monitor for changes in glucose metabolism; long-term cardiovascular safety not established; not indicated for weight loss. U.S. Food and Drug Administration label (original 2010 approval).
- WADA 2026 Prohibited List: growth-hormone-releasing hormone analogues, including tesamorelin, are prohibited in sport under category S2. World Anti-Doping Agency, in force January 2026.